This contributes to tumorigenesis via activating downstream signaling pathways, including PI3K/AKT, JAK-STAT, and MAPK.396 Currently, five SMIs have been approved by FDA for the treatment of NSCLC, which display potently and specifically anti-tumor efficacy, but drug resistance remains a challenge.397,398. Here, AKT1 is linked to neoplasm.